Michael Deininger, MD, PhD | Perspective on Cancer Care in the Time of COVID-19

Michael Deininger, MD, PhD | Addressing Patients on Cancer Care in the Time of COVID-19Подробнее

Downregulation of MS4A3 promotes TKI resistance in CMLПодробнее

Cancer care in the time of COVID-19Подробнее

Debate: Is It Time for Discontinuing TKI Therapy in CML Patients Outside of Clinical Trials?Подробнее

ASCO22 Leukemia Updates | Michael Deininger, MD, PhD | VersitiПодробнее

The impact of the COVID-19 pandemic on cancer care and researchПодробнее

The medium and long-term impacts of COVID-19 on cancer careПодробнее

Treating cancer during the COVID-19 pandemicПодробнее

Disparities in cancer care during COVID-19Подробнее

Impact of COVID-19 on cancer careПодробнее

Impact of COVID-19 on the management of MDSПодробнее

ICAHO 2016 - Dr. Deininger - Chronic Myeloid LeukemiaПодробнее

The Intersection of Cancer and Aging - WexMed Talks | Ohio State Medical CenterПодробнее

Cancer care – additional challenges during and after the pandemicПодробнее

The multidisciplinary care of cancerПодробнее

Mayo Clinic Minute: How COVID-19 has affected cancer careПодробнее

RadVax trial: nivolumab and low-dose radiation in patients with R/R Hodgkin lymphomaПодробнее

Conquering Cancer: Personalized Cancer CareПодробнее